A targeted ultrasound contrast agent for enhancing ultrasound diagnosis of lower extremity arteriosclerosis and its preparation method

Abstract

The invention relates to a targeted ultrasound contrast agent for enhancing the ultrasonic diagnosis of arteriosclerosis of the lower extremities and a preparation method thereof. The peptide is prepared to realize the enrichment of the contrast agent in the affected area of ​​arteriosclerosis of the lower extremities, significantly prolong the duration of contrast, and significantly enhance the ultrasonic imaging effect of arteriosclerosis of the lower extremities.

Description

technical field [0001] The invention belongs to the field of diagnostic reagents, and in particular relates to a targeted ultrasound contrast agent for enhancing ultrasound diagnosis of arteriosclerosis of the lower extremities and a preparation method thereof. Background technique [0002] Ultrasound diagnosis refers to the use of ultrasonic beams to scan tissue structures and process the received signals to obtain morphological images of tissues and organs for disease diagnosis. It has the incomparable advantages of non-invasive, intuitive, radiation-free and other inspection methods . Because ultrasound tissue characterization is not ideal in some tissues, ultrasound contrast agents have emerged as the times require. Ultrasound contrast agents refer to substances that can enhance image contrast in ultrasound diagnosis, and can improve the sensitivity and specificity of ultrasound diagnosis. Existing ultrasound contrast agents include Optison, Sonazoid, Sonovue, Definity,...

AI Technical Summary

Problems solved by technology

Although there have been reports on the application of ultrasound contrast agents in the ultrasound diagnosis of arteriosclerosis of the lower extremities, such as Wu Dongmei et al. reported the application of SonoVue in ultrasound contrast-enhanced ultrasound to evaluate skeletal muscle perfusion disorders in venosclerosis obliterans of the lower extremities; Wang Wei et al. also reported Sonove has diagnostic value for arteriosclerosis of the lower extremities, but in the process of venous diagnosis of the lower extremities, because Sonove cannot target the affected area of ​​arteriosclerosis of the lower extremities, the required dose of contrast agent is high, and the contrast duration is very short. Generally, the effect is only 5 minutes, and the detection window period is short. The continuous administration of a large amount of contrast agent not only has low patient compliance, but also is expensive and has certain side effects, which cannot effectively meet the needs of detailed clinical ultrasound examinations.